RecruitingNCT02346435
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Sponsor
Abramson Cancer Center at Penn Medicine
Enrollment
600 participants
Start Date
Jan 1, 2009
Study Type
OBSERVATIONAL
Conditions
Summary
Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria3
- Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.
- Age ≥ 18 and able to read, understand and sign informed consent.
- Must be willing to adhere to the treatment algorithm and time constraints therein.
Exclusion Criteria1
- Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02346435
Related Trials
Clinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Management of Localized Renal Cell Carcinoma
NCT072344091 location
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
NCT069033121 location
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
NCT048239235 locations
German National Registry for NSS
NCT046816905 locations
Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma
NCT064670971 location